CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 25 filers reported holding CATABASIS PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $0 | -100.0% | 13 | -99.1% | 0.00% | – |
| Q2 2017 | $2,000 | 0.0% | 1,426 | +9.7% | 0.00% | – |
| Q1 2017 | $2,000 | -60.0% | 1,300 | -9.9% | 0.00% | -100.0% |
| Q4 2016 | $5,000 | -28.6% | 1,443 | +20.5% | 0.00% | 0.0% |
| Q3 2016 | $7,000 | +250.0% | 1,198 | +290.2% | 0.00% | – |
| Q4 2015 | $2,000 | -97.7% | 307 | -97.1% | 0.00% | -100.0% |
| Q3 2015 | $87,000 | +987.5% | 10,764 | +1561.1% | 0.01% | +700.0% |
| Q2 2015 | $8,000 | – | 648 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,857,667 | $4,572,000 | 5.05% |
| Clarus Ventures, LLC | 2,752,488 | $4,404,000 | 3.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 388,030 | $621,000 | 0.12% |
| Rhenman & Partners Asset Management AB | 310,756 | $497,000 | 0.08% |
| BOSTON FAMILY OFFICE LLC | 24,467 | $39,000 | 0.01% |
| OPPENHEIMER & CO INC | 90,000 | $144,000 | 0.00% |
| Alyeska Investment Group, L.P. | 221,281 | $354,000 | 0.00% |
| A.R.T. Advisors, LLC | 46,747 | $74,000 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 101,347 | $162,000 | 0.00% |
| Acrospire Investment Management LLC | 680 | $1,000 | 0.00% |